BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse Effects of GLP-1 Receptor Agonists. Rev Diabet Stud 2014;11:202-30. [PMID: 26177483 DOI: 10.1900/RDS.2014.11.202] [Cited by in Crossref: 79] [Cited by in F6Publishing: 37] [Article Influence: 11.3] [Reference Citation Analysis]
Number Citing Articles
1 Hanchard J, Capó-Vélez CM, Deusch K, Lidington D, Bolz SS. Stabilizing Cellular Barriers: Raising the Shields Against COVID-19. Front Endocrinol (Lausanne) 2020;11:583006. [PMID: 33101215 DOI: 10.3389/fendo.2020.583006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Fushimi N, Shibuya T, Yoshida Y, Ito S, Hachiya H, Mori A. Dulaglutide-combined basal plus correction insulin therapy contributes to ideal glycemic control in non-critical hospitalized patients. J Diabetes Investig 2020;11:125-31. [PMID: 31168938 DOI: 10.1111/jdi.13093] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
3 Ghanizada H, Christensen RH, Al-Karagholi MA, Elbahi FA, Coskun H, Ashina M. Arterial responses to infusion of glucagon-like peptide-1 in humans: A randomized trial study. Peptides 2022;150:170736. [PMID: 35017010 DOI: 10.1016/j.peptides.2022.170736] [Reference Citation Analysis]
4 Oberle MM, Kelly AS. It Is Time to Consider Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth. Front Endocrinol (Lausanne) 2019;10:738. [PMID: 31736876 DOI: 10.3389/fendo.2019.00738] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
5 Jin S, Hu W. Severity of COVID-19 and Treatment Strategy for Patient With Diabetes. Front Endocrinol (Lausanne) 2021;12:602735. [PMID: 33995267 DOI: 10.3389/fendo.2021.602735] [Reference Citation Analysis]
6 Ohbayashi K, Oyama Y, Yamaguchi C, Asano T, Yada T, Iwasaki Y. Gastrointestinal Distension by Pectin-Containing Carbonated Solution Suppresses Food Intake and Enhances Glucose Tolerance via GLP-1 Secretion and Vagal Afferent Activation. Front Endocrinol (Lausanne) 2021;12:676869. [PMID: 34168616 DOI: 10.3389/fendo.2021.676869] [Reference Citation Analysis]
7 Yoon HS, Cho CH, Yun MS, Jang SJ, You HJ, Kim JH, Han D, Cha KH, Moon SH, Lee K, Kim YJ, Lee SJ, Nam TW, Ko G. Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice. Nat Microbiol. 2021;6:563-573. [PMID: 33820962 DOI: 10.1038/s41564-021-00880-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
8 Failli M, Paananen J, Fortino V. Prioritizing target-disease associations with novel safety and efficacy scoring methods. Sci Rep 2019;9:9852. [PMID: 31285471 DOI: 10.1038/s41598-019-46293-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
9 Pourheydar M, Hasanzadeh S, Razi M, Pourheydar B, Najafi G. Effects of liraglutide on sperm characteristics and fertilization potential following experimentally induced diabetes in mice. Vet Res Forum 2021;12:109-16. [PMID: 33953881 DOI: 10.30466/vrf.2019.96822.2315] [Reference Citation Analysis]
10 Rana KB, Britnell SR, Gilbertson ME, Ibrahim SL. Comparison of the Effectiveness of Liraglutide vs Semaglutide in a Veteran Population. J Pharm Pract 2022;:8971900221087127. [PMID: 35414304 DOI: 10.1177/08971900221087127] [Reference Citation Analysis]
11 Fontaine AK, Ramirez DG, Littich SF, Piscopio RA, Kravets V, Schleicher WE, Mizoguchi N, Caldwell JH, Weir RFF, Benninger RKP. Optogenetic stimulation of cholinergic fibers for the modulation of insulin and glycemia. Sci Rep 2021;11:3670. [PMID: 33574598 DOI: 10.1038/s41598-021-83361-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Moran GW, Thapaliya G. The Gut-Brain Axis and Its Role in Controlling Eating Behavior in Intestinal Inflammation. Nutrients 2021;13:981. [PMID: 33803651 DOI: 10.3390/nu13030981] [Reference Citation Analysis]
13 Patel H. The role of the lateral septum in neuropsychiatric disease. J Neurosci Res 2022. [PMID: 35443088 DOI: 10.1002/jnr.25052] [Reference Citation Analysis]
14 Campos C, Unger J. Primary care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Postgrad Med 2021;133:843-53. [PMID: 34416133 DOI: 10.1080/00325481.2021.1971461] [Reference Citation Analysis]
15 Hompesch M, Kang J, Han O, Trautmann ME, Sorli CH, Ogbaa I, Stewart J, Morrow L. Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study. BMJ Open Diabetes Res Care 2021;9:e002208. [PMID: 34172436 DOI: 10.1136/bmjdrc-2021-002208] [Reference Citation Analysis]
16 Fadah K, Alashi A, Deoker A. The Enhanced Cardiac Outcome of Conjugated SGLT2 Inhibitors and GLP-1RA Therapy in Diabetic Patients. Curr Cardiol Rep 2022. [PMID: 35000149 DOI: 10.1007/s11886-021-01619-8] [Reference Citation Analysis]
17 Zhong X, Chen Z, Chen Q, Zhao W, Chen Z. Novel Site-Specific Fatty Chain-Modified GLP-1 Receptor Agonist with Potent Antidiabetic Effects. Molecules 2019;24:E779. [PMID: 30795583 DOI: 10.3390/molecules24040779] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
18 Lyseng-Williamson KA. Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes: Their Use and Differential Features. Clin Drug Investig 2019;39:805-19. [PMID: 31317516 DOI: 10.1007/s40261-019-00826-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
19 Gill L, Mackey S. Obstetrician-Gynecologists' Strategies for Patient Initiation and Maintenance of Antiobesity Treatment with Glucagon-Like Peptide-1 Receptor Agonists. J Womens Health (Larchmt) 2021;30:1016-27. [PMID: 33626287 DOI: 10.1089/jwh.2020.8683] [Reference Citation Analysis]
20 Jain N, Savani M, Agarwal M, Sands CW. Albiglutide-induced pancreatitis. Ther Adv Drug Saf 2016;7:236-8. [PMID: 27904741 DOI: 10.1177/2042098616667352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Hasanzad M, Sarhangi N, Nikfar S, Ostad SN, Aghaei Meybodi HR. A narrative review of current trends in liraglutide: insights into the unmet needs in management of type 2 diabetes and obesity. J Diabetes Metab Disord 2020;19:1863-72. [PMID: 33520865 DOI: 10.1007/s40200-020-00619-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
22 Hearn EB, Sherman JJ. Injection-Site Nodules Associated With Once-Weekly Subcutaneous Administration of Semaglutide. Diabetes Spectr 2021;34:73-5. [PMID: 33627997 DOI: 10.2337/ds20-0033] [Reference Citation Analysis]
23 Zhao Z, Tang Y, Hu Y, Zhu H, Chen X, Zhao B. Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data. Ann Transl Med 2021;9:1482. [PMID: 34734034 DOI: 10.21037/atm-21-4162] [Reference Citation Analysis]
24 Onoviran OF, Li D, Toombs Smith S, Raji MA. Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus. Ther Adv Chronic Dis 2019;10:2040622319862691. [PMID: 31321014 DOI: 10.1177/2040622319862691] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
25 Alexopoulos AS, Buse JB. Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin. Metabolism 2019;98:104-11. [PMID: 31255662 DOI: 10.1016/j.metabol.2019.06.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
26 Frias JP, Nauck MA, Van J, Benson C, Bray R, Cui X, Milicevic Z, Urva S, Haupt A, Robins DA. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes Obes Metab 2020;22:938-46. [PMID: 31984598 DOI: 10.1111/dom.13979] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 13.0] [Reference Citation Analysis]
27 Mouhammad ZA, Vohra R, Horwitz A, Thein A, Rovelt J, Cvenkel B, Williams PA, Azuara-blanco A, Kolko M. Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma? Front Neurosci 2022;16:824054. [DOI: 10.3389/fnins.2022.824054] [Reference Citation Analysis]
28 Xiang L, Thompson MS, Clemmer JS, Mittwede PN, Khan T, Hester RL. Early treatment with GLP-1 after severe trauma preserves renal function in obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 2019;316:R621-7. [PMID: 30811247 DOI: 10.1152/ajpregu.00312.2018] [Reference Citation Analysis]
29 Kalra S, Das AK, Sahay RK, Baruah MP, Tiwaskar M, Das S, Chatterjee S, Saboo B, Bantwal G, Bhattacharya S, Priya G, Chawla M, Brar K, Raza SA, Aamir AH, Shrestha D, Somasundaram N, Katulanda P, Afsana F, Selim S, Naseri MW, Latheef A, Sumanatilleke M. Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force. Diabetes Ther 2019;10:1645-717. [PMID: 31359367 DOI: 10.1007/s13300-019-0669-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
30 Romera I, Cebrián-Cuenca A, Álvarez-Guisasola F, Gomez-Peralta F, Reviriego J. A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes. Diabetes Ther 2019;10:5-19. [PMID: 30506340 DOI: 10.1007/s13300-018-0535-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
31 Ahmad E, Sargeant JA, Zaccardi F, Khunti K, Webb DR, Davies MJ. Where Does Metformin Stand in Modern Day Management of Type 2 Diabetes? Pharmaceuticals (Basel) 2020;13:E427. [PMID: 33261058 DOI: 10.3390/ph13120427] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Iwasaki Y, Sendo M, Dezaki K, Hira T, Sato T, Nakata M, Goswami C, Aoki R, Arai T, Kumari P, Hayakawa M, Masuda C, Okada T, Hara H, Drucker DJ, Yamada Y, Tokuda M, Yada T. GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose. Nat Commun 2018;9:113. [PMID: 29317623 DOI: 10.1038/s41467-017-02488-y] [Cited by in Crossref: 60] [Cited by in F6Publishing: 50] [Article Influence: 15.0] [Reference Citation Analysis]
33 Enomoto K, Kosaka C, Kimura T, Watanuki S, Kurihara M, Watari T, Schaye V. Pharmacists can improve diagnosis and help prevent diagnostic errors. Diagnosis (Berl) 2022. [PMID: 35089657 DOI: 10.1515/dx-2021-0138] [Reference Citation Analysis]
34 Wang W, Wen X, Duan W, Wang X, Chen Y, Dong J, Yang Z, Fang J, Zhou Z, Yao G, Fang Y, Huang Y. DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus. J Endocrinol Invest 2020;43:653-62. [PMID: 31786794 DOI: 10.1007/s40618-019-01153-z] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Shi N, Shi Y, Xu J, Si Y, Yang T, Zhang M, Ng DM, Li X, Xie F. SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Front Public Health 2021;9:668368. [PMID: 34164370 DOI: 10.3389/fpubh.2021.668368] [Reference Citation Analysis]
36 Cristelo C, Azevedo C, Marques JM, Nunes R, Sarmento B. SARS-CoV-2 and diabetes: New challenges for the disease. Diabetes Res Clin Pract 2020;164:108228. [PMID: 32446801 DOI: 10.1016/j.diabres.2020.108228] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 15.0] [Reference Citation Analysis]
37 Lim J, Ferruzzi MG, Hamaker BR. Dietary starch is weight reducing when distally digested in the small intestine. Carbohydr Polym 2021;273:118599. [PMID: 34560999 DOI: 10.1016/j.carbpol.2021.118599] [Reference Citation Analysis]
38 Hale C, Véniant MM. Growth differentiation factor 15 as a potential therapeutic for treating obesity. Mol Metab 2021;46:101117. [PMID: 33220493 DOI: 10.1016/j.molmet.2020.101117] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
39 Subbaram K, Ali PSS, Ali S. Enhanced endocytosis elevated virulence and severity of SARS-CoV-2 due to hyperglycemia in type 2 diabetic patients. Gene Rep 2022;26:101495. [PMID: 35043090 DOI: 10.1016/j.genrep.2022.101495] [Reference Citation Analysis]
40 Hope DCD, Vincent ML, Tan TMM. Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity. Front Endocrinol (Lausanne) 2021;12:735019. [PMID: 34566894 DOI: 10.3389/fendo.2021.735019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Shepard BD, Ecelbarger CM. Sodium Glucose Transporter, Type 2 (SGLT2) Inhibitors (SGLT2i) and Glucagon-Like Peptide 1-Receptor Agonists: Newer Therapies in Whole-Body Glucose Stabilization. Semin Nephrol 2021;41:331-48. [PMID: 34715963 DOI: 10.1016/j.semnephrol.2021.06.005] [Reference Citation Analysis]
42 Frias JP, Dex T, Roberts M, Kaplan A. A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide. Diabetes Ther 2019;10:21-33. [PMID: 30539523 DOI: 10.1007/s13300-018-0547-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
43 Goldman JD. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes. J Clin Pharm Ther 2020;45 Suppl 1:61-72. [PMID: 32910492 DOI: 10.1111/jcpt.13226] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Johann K, Kleinert M, Klaus S. The Role of GDF15 as a Myomitokine. Cells 2021;10:2990. [PMID: 34831213 DOI: 10.3390/cells10112990] [Reference Citation Analysis]
45 Turk Wensveen T, Gašparini D, Rahelić D, Wensveen FM. Type 2 diabetes and viral infection; cause and effect of disease. Diabetes Res Clin Pract 2021;172:108637. [PMID: 33352263 DOI: 10.1016/j.diabres.2020.108637] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
46 Ja'arah D, Al Zoubi MS, Abdelhady G, Rabi F, Tambuwala MM. Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia. Clin Med Insights Endocrinol Diabetes 2021;14:11795514211051697. [PMID: 34690504 DOI: 10.1177/11795514211051697] [Reference Citation Analysis]
47 Luo D, Dong X, Huang J, Huang C, Fang G, Huang Y. Pueraria lobata root polysaccharide alleviates glucose and lipid metabolic dysfunction in diabetic db/db mice. Pharm Biol 2021;59:382-90. [PMID: 33794128 DOI: 10.1080/13880209.2021.1898648] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Borse SP, Chhipa AS, Sharma V, Singh DP, Nivsarkar M. Management of Type 2 Diabetes: Current Strategies, Unfocussed Aspects, Challenges, and Alternatives. Med Princ Pract 2021;30:109-21. [PMID: 32818934 DOI: 10.1159/000511002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
49 Gater A, Reaney M, Findley A, Brun-Strang C, Burrows K, Nguyên-Pascal ML, Roborel de Climens A. Development and First Use of the Patient's Qualitative Assessment of Treatment (PQAT) Questionnaire in Type 2 Diabetes Mellitus to Explore Individualised Benefit-Harm of Drugs Received During Clinical Studies. Drug Saf 2020;43:119-34. [PMID: 31679129 DOI: 10.1007/s40264-019-00877-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 Farr OM, Sofopoulos M, Tsoukas MA, Dincer F, Thakkar B, Sahin-Efe A, Filippaios A, Bowers J, Srnka A, Gavrieli A, Ko BJ, Liakou C, Kanyuch N, Tseleni-Balafouta S, Mantzoros CS. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial. Diabetologia 2016;59:954-65. [PMID: 26831302 DOI: 10.1007/s00125-016-3874-y] [Cited by in Crossref: 101] [Cited by in F6Publishing: 97] [Article Influence: 16.8] [Reference Citation Analysis]
51 Gao L, Yu S, Cipriani A, Wu S, Huang Y, Zhang Z, Yang J, Sun Y, Yang Z, Chai S, Zhang Y, Ji L, Zhan S, Sun F. Neurological Manifestation of Incretin-Based Therapies in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Aging Dis 2019;10:1311-9. [PMID: 31788342 DOI: 10.14336/AD.2019.0303] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
52 Rehani PR, Iftikhar H, Nakajima M, Tanaka T, Jabbar Z, Rehani RN. Safety and Mode of Action of Diabetes Medications in comparison with 5-Aminolevulinic Acid (5-ALA). J Diabetes Res 2019;2019:4267357. [PMID: 31781665 DOI: 10.1155/2019/4267357] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]